News

ERA-EDTA, May 24-27, Paris, France May 08 2012

BioPorto Diagnostics Product overview 2012 March 02 2012

ISICEM 2012, March 20-23, Brussels, Belgium February 23 2012

CRITICARE, February 15-19, Pune, India January 24 2012

Conference on Continuous Renal Replacement Therapies (CRRT), February 12-15, San Diego, USA January 24 2012

MEDLAB, Arab Health, January 23-26, Dubai, UAE January 16 2012

An addition to the Obesity and Type 2 Diabetes antibody portfolio December 22 2011

Better kidney markers ahead? December 05 2011

New NGAL.com website launched November 24 2011

MEDICA, November 16-19, Düsseldorf, Germany October 26 2011

next 10

AACC Clinical Lab Expo, July 24-28, Atlanta

July 04 2011 by BioPorto Diagnostics

The AACC/Clinical Laboratory Expo is the leading event for clinical chemistry, clinical laboratory science and laboratory medicine products and services.

20.000 participants are expected and BioPorto Diagnostic will be promoting The NGAL Test™, which is CE IVD registered for diagnostic use in Europe and available for research use only in the United States.

What is NGAL?
NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). NGAL provides a new way to identify patients at risk of developing potentially severe acute kidney injury (AKI).

For more information about NGAL please visitwww.ngal.com

BioPorto Diagnostics will be represented at the AACC/Clinical Laboratory Expo with an exhibition stand. Meet Jakob Ohm Eriksen, Product Manager joe@bioporto.com, Elaine Lundberg, Product Manager eal@bioporto.com and Trine Østerbye, Sales and Marketing Manager toe@bioporto.com at booth nr. 2809.

For further information on the event please visit: http://www.aacc.org/events/2011am/expo/pages/default.aspx